013 Unabated type I interferon expedites B-cell autoimmunity and anti-drug antibody formation during anti-TNF therapy
Anti-TNFs have become a benchmark in the treatment of numerous autoimmune diseases such as rheumatoid arthritis, Crohn ’s disease, and psoriasis. However, TNF blockade as a therapy has its limitations. Besides an increased susceptibility to infections, 0.2-1% of patients develop anti-TNF induced lupus erythematosus (ATIL). Moreover, anti-TNFs are associated with increased frequencies of anti-drug antibodies (ADA). We have previously shown that TNF inhibition shifts the equilibrium of TNF and type I interferons towards an excessive type I interferon response.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: A. Mennella, A. Mylonas, J. Chen, A. Nidegger, M. Gilliet, R. Lande, L. Frasca, C. Conrad Source Type: research
More News: Arthritis | Autoimmune Disease | Crohn's Disease | Dermatology | Lupus | Men | Psoriasis | Rheumatoid Arthritis | Rheumatology | Skin